EACR Conference on Cancer Metabolism
11 - 13 October 2022
Bilbao, Spain

Pocket Programme

Scientific Programme Committee
Arkaitz Carracedo (Chair)
Christian Frezza
Sarah-Maria Fendt
Sara Zanivan

Scan the QR code to access online conference resources, including speaker and poster abstracts

eacr.org/conference/cancermetabolism2022
Conference Dinner

Optional Ticketed Event, Wednesday 12 October, 19:30 CEST - SOLD OUT

The Conference Dinner will take place at Kafe Antzokia’s Restaurant. It will be an excellent opportunity for participants and speakers to get to know each other in a relaxed and informal environment. After dinner, we will enjoy music and dancing with a live DJ.

Kafe Antzokia’s Restaurant: Done Bikendi Kalea, 2, 48001 Bilbo, Bizkaia, Spain
Day 1 - Tuesday 11 October

From 12.00

REGISTRATION

12.00 – 13.00

WELCOME LUNCH & EXHIBITION
A chance to meet fellow participants and enjoy a light buffet lunch before the first session.

13.00 – 13.10

CONFERENCE WELCOME
Scientific Programme Committee

SESSION 1: METABOLIC WIRING IN CANCERS
Chair: Arkaitz Carracedo

13.10 – 13.40

OPENING KEYNOTE

Q&A: 13.40 – 13.55

Ralph DeBerardinis Children’s Medical Center Research Institute, USA
“Tumor Metabolism and Cancer Progression in Humans”

Sarah-Maria Fendt VIB Leuven, Belgium
“The role of metabolism in metastasis formation”

Eva Crosas-Molist Barts Cancer Institute, UK
Proffered Paper 1: “AMPK is a mechano-metabolic sensor linking cell adhesion and mitochondrial dynamics to Myosin II dependent cell migration”

13.55 – 14.15

Q&A: 14.15 – 14.25

14.25 – 14.35

Q&A: 14.35 – 14.40

EXHIBITOR INTRODUCTIONS

14.40 – 14.50

COFFEE BREAK & EXHIBITION
Chair: Sarah-Maria Fendt

14.50 – 15.20

15.20 – 15.40

Proffered Paper 1: “AMPK is a mechano-metabolic sensor linking cell adhesion and mitochondrial dynamics to Myosin II dependent cell migration”

Matthew Vander Heiden Koch Institute, MIT, USA
“Metabolic limitations in Cancer”
<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Institution</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>15.50 - 16.10</td>
<td><strong>Oliver Maddocks</strong> University of Glasgow, UK</td>
<td>&quot;Cancer specific amino acid metabolism&quot;</td>
<td></td>
</tr>
<tr>
<td>Q&amp;A: 16.10 - 16.20</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.20 - 16.40</td>
<td><strong>Arkaitz Carracedo</strong> CIC bioGUNE, Spain</td>
<td>&quot;Metabolic drivers of prostate cancer progression beyond the tumor cell&quot;</td>
<td></td>
</tr>
<tr>
<td>Q&amp;A: 16.40 - 16.50</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.50 - 17.00</td>
<td><strong>POSTER SPOTLIGHTS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.00 - 18.00</td>
<td><strong>WELCOME RECEPTION</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18.00 - 19.30</td>
<td><strong>POSTER DISCUSSION SESSION 1</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Day 2 - Wednesday 12 October**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Institution</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30 - 08.45</td>
<td><strong>POSTER VIEWING</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08.45 - 09.00</td>
<td><strong>INDUSTRY SPOTLIGHT - AGILENT TECHNOLOGIES</strong></td>
<td><strong>Alfredo Caro-Maldonado</strong></td>
<td>University of Birmingham, UK</td>
<td>&quot;How to develop and predict the efficiency of T cell therapies by immunometabolism&quot;</td>
</tr>
<tr>
<td>09.00 - 09.20</td>
<td><strong>EMBO KEYNOTE LECTURE</strong></td>
<td><strong>Massimiliano Mazzone</strong> University of Leuven, Belgium</td>
<td>&quot;Harnessing tumor metabolism to overcome immunosuppression&quot;</td>
<td></td>
</tr>
<tr>
<td>Q&amp;A: 09.20 - 09.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.30 - 09.40</td>
<td><strong>Proffered Paper 2</strong></td>
<td><strong>Lisa Vettore</strong> University of Birmingham, UK</td>
<td>&quot;Proline biosynthesis through PYCRL regenerates NAD+ to promote cancer stem-like cells proliferation and survival under hypoxic conditions&quot;</td>
<td></td>
</tr>
<tr>
<td>Q&amp;A: 09.40 - 09.45</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.45 - 10.05</td>
<td><strong>Salvador Aznar Benitah</strong></td>
<td>Institute for Research in Biomedicine, Spain</td>
<td>&quot;Epigenetic influence of our (fatty) diet on metastatic-initiating cells&quot;</td>
<td></td>
</tr>
<tr>
<td>Q&amp;A: 10.05 - 10.15</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.15 - 10.35</td>
<td><strong>Theodore Alexandrov</strong></td>
<td>European Molecular Biology Laboratory, Germany</td>
<td>&quot;Spatial metabolomics in tissues and single cells&quot;</td>
<td></td>
</tr>
<tr>
<td>Q&amp;A: 10.35 - 10.45</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>--------------------------------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.45 – 11.15</td>
<td><strong>COFFEE BREAK &amp; EXHIBITION</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.15 – 11.45</td>
<td>KEYNOTE LECTURE</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Q&A: 11.45 – 12.00 | Joshua Rabinowitz  
Institute for Integrative Genomics, USA  
“The energy budget of tumors in vivo” |
| 12.00 – 12.10| Tobias Ackermann                             |
| Q&A: 12.10 – 12.15 | Proffered Paper 3: “Secreted mono-unsaturated fatty acids are paracrine anti-ferroptotic factors in triple-negative breast cancer cells” |
| 12.15 – 12.25| POSTER SPOTLIGHTS                           |
| 12.25 – 13.20| **LUNCH & EXHIBITION**                      |
| 13.20 – 14.50| POSTER DISCUSSION SESSION 2                |
| 14.50 – 15.20| KEYNOTE LECTURE                            |
| Q&A: 15.20 – 15.35 | Celeste Simon  
Abramson Family Cancer Research Institute, USA  
“Exploring Tumor Neighbourhoods” |
| 15.35 – 15.55| Katrien De Bock                              |
| Q&A: 15.55 – 16.05 | ETH Zurich, Switzerland  
“Endothelial cells and metabolism in the muscle microenvironment” |
| 16.05 – 16.15| Debbie Moss                                 |
| Q&A: 16.15 – 16.20 | Queen’s University Belfast, UK  
Proffered Paper 4: “Oxidative Mitochondrial Metabolism: A Key Driver of Therapy Resistance in Colorectal Cancer” |
| 16.20 – 16.30| Fabricio Loayza-Puch                         |
| Q&A: 16.30 – 16.35 | DKFZ, Germany  
Proffered Paper 5: “Exploiting mitochondrial translation to uncover compartment-specific metabolic vulnerabilities” |
| 16.35 – 17.05| **COFFEE BREAK & EXHIBITION**              |
| 17.05 – 17.25| Sara Zanivan                                 |
| Q&A: 17.25 – 17.35 | Beatson Institute, UK  
“CAF metabolism coordinates extracellular matrix production” |

*Posters 79-158 can be put up.*
17.35 - 17.55  Ilaria Elia University of Leuven, Belgium
            “The metabolic cross-talk between T cells and tumor cells in the tumor microenvironment”

18.05 - 18.45  MEET THE EDITORS
            Join us in this informal session to meet Alfredo Gimenez-Cassina (Nature Metabolism), Maria Garcia-Fernandez (Nature Communications) and Barbara Marte (Nature) and ask questions in a relaxed and informal setting.

19.30  OPTIONAL CONFERENCE DINNER
            at the Kafe Antzokia’s Restaurant for those who have purchased tickets [sold-out].

Day 3 - Thursday 13 October

08.30 - 08.45  POSTER VIEWING

08.45 - 09.00  INDUSTRY SPOTLIGHT - PARSE BIOSCIENCES
            Mostafa ElMaghraby
            "Resolving More Biology Using the Evercode Platform for Single Cell RNA Sequencing"

09.00 - 09.45  MEET THE MEMBERS OF THE SCIENTIFIC PROGRAMME COMMITTEE
            This is an opportunity for all participants to get to know, and ask questions to Arkaitz, Christian, Sarah-Maria and Sara in an informal setting.

SESSION 4: CANCER METABOLISM AND THE REGULATION OF THE EPIGENOME
            Chair: Sara Zanivan

09.45 - 10.05  Christian Frezza University Hospital Cologne, Germany
            “The chronology of FH loss”

10.15 - 10.35  Andreas Trumpp DKFZ, Germany
            “Metabolism in normal and malignant stem cells”

10.45 - 11.15  COFFEE BREAK & EXHIBITION

11.15 - 11.35  Sonia Rocha Institute of Integrative Biology/Biochemistry, UK
            “Chromatin as a metabolic sensor in the cell”
EACR-Worldwide Cancer Research Meeting Bursary Awards

More information about EACR bursaries: eacr.org/meeting-bursary

EACR-Worldwide Cancer Research Meeting Bursaries provide funds to help early-career EACR members and researchers based in low- or middle-income economy countries to participate in our conferences.

Congratulations to the recipients of the Meeting Bursaries for this conference. Each winner received a full registration free of charge and funds of up to €500 to assist with the cost of travel and accommodation.

- Yunus Akkoç  Turkey
- Natividad Alquezar-Artieda  Czech Republic
- Kimberley Hanssen  Australia
- Greta Matavelli  Germany
- Debbie Moss  UK
- Shivang Sunil Parikh  Israel
- Lisa Vettore  UK
Venue Floorplan

Lecture theatre

Poster boards and catering

Exhibitors
1. Parse Biosciences
2. Agilent Technologies
3. TargetMol
4. Symcel
5. Don Whitley Scientific
6. CancerTools.org
7. Cibertec
8. De Gruyter

EACR Conference on Cancer Metabolism
Bilbao, Spain | 11 - 13 October 2022
Meet the Exhibitors

**Parse Biosciences**  Stand: 1  
Website: www.parsebiosciences.com  
Represented at the conference by: Mostafa ElMaghraby, Natalia Juiz  
**Spotlight:** Thursday 13 October 2022 | 08.45-09.00  

**Agilent Technologies**  Stand: 2  
Website: www.agilent.com  
Represented at the conference by: Alfredo Caro Maldonado  
**Spotlight:** Wednesday 12 October 2022 | 08.45-09.00  
Alfredo Caro-Maldonado: “How to develop and predict the efficiency of T cell therapies by immunometabolism”

**TargetMol**  Stand: 3  
Website: www.targetmol.com  
Represented at the conference by: Hong Chen

**Symcel**  Stand: 4  
Website: symcel.com  
Represented at the conference by: Eddie Modig, Ganna Oliynyk

**Don Whitley Scientific**  Stand: 5  
Website: www.dwscientific.com  
Represented at the conference by: Alun Kitsell, Covadonga Garcia, Joaquin Mateo Urdiales

**CancerTools.org**  Stand: 6  
Website: www.cancertools.org  
Represented at the conference by: Julia Appelhans, Jacob Jayaratnasingam
Meet the Exhibitors

**Cibertec**  
Stand: 7  
Website: [www.cibertec.es](http://www.cibertec.es)  
Represented at the conference by:  
Xavier Cañis, Irina Distergoft

---

**De Gruyter**  
Stand: 8  
Website: [www.degruyter.com](http://www.degruyter.com)  
Represented at the conference by:  
Magdalena Wierzchowiecka-Pańczak, Izabela Żarczyńska

---

Media Partner:  
![nature metabolism](#)  
Keynote Lecture Sponsor:  
![EMBO](#)

Grant:  
![Pfizer](#)  
![Bilbao](#)
001 [POSTER SPOTLIGHT] Restored biosynthetic pathways induced by MSCs serve as a rescue mechanism in leukemia cells after L-asparaginase therapy
   Presented by Natividad Alquezar-Artieda, Charles University, Prague, CZECH REPUBLIC

002 [POSTER SPOTLIGHT] A palmitate-rich metastatic niche promotes metastasis formation via NF-κB acetylation
   Presented by Patricia Altea-Manzano, VIB Center for Cancer Biology | KU Leuven and Leuven Cancer Institute (LKI), Leuven, BELGIUM

003 [POSTER SPOTLIGHT] The regulators of peroxisomal acyl-carnitine shuttle CROT and CRAT promote metastasis in melanoma
   Presented by Imanol Arozarena, Navarrabiomed-Idisna, Pamplona, SPAIN

004 Inhibition of Ocular Tumor and Endothelial Cell Growth with a TEAD4216 Peptide Fragment
   Presented by Bissan Ahmed, Arab International University, Daraa, SYRIA

005 A Precision Medicine Approach to Metabolic Therapy for Breast Cancer in Mice
   Presented by Ngozi Akingbesote, Yale School of Medicine, New Haven, Connecticut, USA

006 Tumor-derived CTF1 (cardiotrophin 1) is a critical mediator of stroma-assisted and autophagy-dependent breast cancer cell migration, invasion and metastasis
   Presented by Yunus Akkoc, Koç University School of Medicine, Istanbul, TURKEY, | SUNUM, Istanbul, TURKEY

007 UCP2 silencing restrains leukemia cell proliferation through glutamine metabolic remodeling
   Presented by Marie-Clotilde Alves-Guerra, Université Paris Cité, CNRS, INSERM, Institut Cochin, F-75014 Paris, FRANCE

008 Design and validation of PYCR1 inhibitors for cancer therapy
   Presented by Marc Aragó, University of Barcelona, L’Hospitalet del Llobregat, SPAIN

009 Potential liquid biopsy-based biomarkers for diagnosis and prognosis of meningioma through metabolomics analysis
   Presented by Gabriel Araujo Kurokawa, São Paulo State University (Unesp), Botucatu, São Paulo, BRAZIL

010 miR-495-3p regulates Sphingolipid metabolic reprogramming in Non-small cell lung cancer via targeting Sphk1
   Presented by Shweta Arora, Jamia Millia Islamia, New Delhi, INDIA

011 Stroma metabolic reprogramming as a regulator of prostate cancer aggressiveness
   Presented by Ianire Astobiza, CICbioGUNE, Derio, SPAIN | CIBERONC, Madrid, SPAIN

012 PDK4 – a novel prognostic marker for prostate cancer
   Presented by Emine Atas, Medical University of Vienna, AUSTRIA

013 Spatiotemporal modelling of the evolution of chemoresistance in breast tumors using integrated omics uncovers key dependency on members of the solute carrier superfamily
   Presented by Yannick Audet-Delage, University of Ottawa, ON, CANADA
014 Deciphering the role of the OSM/OSMR/lactate axis in the breast cancer microenvironment
Presented by Peio Azcoaga, Biodonostia Health Research Institute, San Sebastian, SPAIN | CIC biomaGUNE, San Sebastian, SPAIN

015 Investigating the effect of EGFR on the metabolic diversity of human lung cancer
Presented by Tina Becirovic, Karolinska Institute, Stockholm, SWEDEN

016 Adaptation to ER-stress via serine-glycine metabolism licences STING signalling and CMV control in intestinal epithelial cells
Presented by Björn Becker, Luxembourg Institute of Health, Department of Cancer Research

017 Unraveling leukemia stem cell mitochondrial dependency in pediatric acute myeloid leukemia
Presented by Maddalena Benetton, Department of Women’s and Children’s Health, University of Padova, ITALY

018 Apoptosis of tumour infiltrating lymphocytes is a mechanism of tumour resistance in OSCC
Presented by Priyanka Bhosale, Centre for Gene Therapy & Regenerative Medicine, King’s College London, UK

019 Reprogrammed Valine Catabolism Promotes Mitochondrial Energy Remodelling Throughout Prostate Cancer Progression and Enzalutamide Resistance
Presented by Charles Bidgood, Australian Prostate Cancer Research Centre, Queensland University of Technology, AUSTRALIA

020 Imaging metabolic heterogeneity and enabling lung cancer treatment using dual-tracer PET
Presented by Robert Bielik, Cancer Research UK Beatson Institute, Glasgow, UK

021 Dissecting cell-cell interactions using fluorescent metabolite sensors
Presented by Samuel Block, Koch Institute for Integrative Cancer Research and Department of Biology, MIT, Cambridge, USA

022 tRNA editing-mediated control of redox metabolism unveils new metabolic vulnerabilities in lung cancer
Presented by Arnaud Blomme, GIGA-Institute, University of Liège, BELGIUM

023 Metabolic reprogramming sustains chemotherapy resistance in medulloblastoma
Presented by Roberta Bortolozzi, University of Padova, ITALY | Istituto di Ricerca Pediatrica, Padova, ITALY

024 Protein Homeostasis for the Control of Prostate Cancer Metastasis
Presented by Laura Bozal-Basterra, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Derio, SPAIN

025 Dual-tracer Positron Emission Tomography (PET) for improved tumor energetic and microenvironment phenotyping: an autoradiography-based study
Presented by Morten Busk, Aarhus University Hospital (AUH), DENMARK

026 Loss of Aspartoacylase enzyme (ASPA) reprograms cancer-associated fibroblasts (CAFs) to potentiate tumor progression – potential new regulator of metabolic reprogramming in CAFs
Presented by Fernando Calvo, IBBTEC, CSIC/Università de Cantabria, Santander/Cantabria, SPAIN
027 Characterization of metabolic rewiring and identification of potential therapeutic targets in CBFA2T3-GLIS2-dependent AMKL. Presented by Caroline Capdevielle, Maisonneuve-Rosemont Hospital Research Center, Montréal, QC, CANADA | Université de Montréal, QC, CANADA

028 Changes in glioblastoma cell line lipidome after 2-OHOA treatment through C17:1n-9 incorporation in all lipid families. Presented by Doralicia Casares, Universitat de les Illes Balears, Palma de Mallorca, SPAIN | Laminar Pharmaceuticals, Palma de Mallorca, SPAIN

029 Vitamin C targets Warburg effect in KRAS mutant colorectal cancer, boosting PDH activity. Presented by Aiora Cenigaonandia, IIS-FJD, Madrid, SPAIN

030 A Novel Multi-Sensor Platform for Real-Time Measurement of Cell/Tissue Metabolism. Presented by Thomas Chen, Colorado State University, Fort Collins, USA

031 Role of Mitochondrial DNA Polymerase (POLG) in Breast Cancer. Presented by Chiara Chinghi, University of Salford, Manchester, UK

032 Long-term NRF2 depletion in KRAS-mutated pancreatic cancer cells leads to the activation of metabolic short-circuits sustaining cancer cells fitness and overcoming KRAS addiction. Presented by Himanshi Choudhary, Udine University, ITALY

033 Extracellular Matrix modulates mechanotransduction and metabolic alteration in EC leading to melanoma vascularization. Presented by Michela Corsini, University of Brescia, ITALY

034 Acidosis-induced regulation of adipocyte G0S2 promotes the crosstalk between adipocytes and cancer cells as well as tumor progression. Presented by Julie Cremer, University of Liège, GIGA-Cancer, BELGIUM

035 The effect of lipid synthesis inhibitors on triple positive breast cancer cells proliferation in in-vitro model. Presented by Aleksandra Czumaj, Medical University of Gdańsk, POLAND

036 Hexokinase 2 promotes brain tumour growth by metabolic rewiring. Presented by Leandro de Assis, University of Plymouth, UK

037 Computational models of p53-associated metabolic networks. Presented by Carlo de Blasio, IRCM, Montpellier, FRANCE

038 Lipid Metabolism Rewiring by Long Noncoding RNA MALAT1-Targeting in Prostate Cancer: Focus on Androgen-Dependent Kinases, CHKA and CERK. Presented by Sara De Martino, Università Cattolica del Sacro Cuore, ITALY

039 The Transcription Factor ChREBP Orchestrates Liver Carcinogenesis at the Interface of the Oncogenic PI3K/AKT Signaling and Cancer Cell Metabolism. Presented by Renaud Dentin, INSERM U1016, Paris, FRANCE | CNRS UMR8104, Paris, FRANCE
040 Copper-transporting ATPases as a theranostic target in pancreatic ductal adenocarcinoma presented by Alina Doctor, Helmholtz-Zentrum Dresden-Rossendorf, Germany | Technische Universität Dresden, Germany

041 The metabolic rewiring from glycolysis to FAO of cancer cells underlines their recognition by NK cells presented by Steffy Escayg, INSERM U1183, Montpellier, France | IRMB, Montpellier, France

042 Study of silybin plant effective substance for use in targeted liposomal nanoparticles in the treatment of liver cancer presented by Amir Abbas Esmaeilzadeh, Dayan Company, Tehran, Iran

043 The interplay between PGC1 and the hypoxia signaling in Prostate Cancer presented by Maider Fagoaga, CIC bioGUNE, Derio, Spain

044 Boosting CAR T Cells with Mannose presented by Macarena Lucia Fernandez Carro, The University of Manchester, UK

045 Investigation of metabolic plasticity of cancer cells presented by Filippo Ferrucci, TU Dresden, Germany

046 Metabolic tracing of prostate cancer patient-derived xenografts identifies metabolic heterogeneity and highlights the therapeutic potential of targeting fatty acid metabolism presented by Gio Fidelito, The University of Melbourne, Australia

047 Glycine decarboxylase maintains mitochondrial protein lipoylation to support tumor growth presented by Mariam Fokra, Technion- Israel Institute of Technology, Haifa, Israel

048 Metabolic heterogeneity as a driver of stem cell fate and tumorigenesis presented by Lidia Fortuny, University of Barcelona, Spain

049 Rewiring of growth factor-dependent signalling and metabolism in breast cancer cells presented by Chiara Francavilla, The University of Manchester, UK

050 Effects of phosphatidylserine decarboxylase disruption on metabolism in hormone therapy resistant breast cancer cells presented by Virginia Gamboa-Aldecoa, Cancer Heterogeneity Lab, CIC bioGUNE, Bizkaia, Spain

051 The type of dietary fat influences tumor cell metabolism in breast cancer experimental mammary tumors presented by Maite Garcia Guasch, Universitat Autònoma de Barcelona, Spain

052 NNMT drives the mesenchymal-like phenotype and generates new metabolic vulnerabilities in in EGFR-mutant NSCLC with acquired resistance to tyrosine kinase inhibitors presented by Juan Carlos Garcia-Cañaveras, Instituto de Investigación Sanitaria La Fe, Valencia, Spain

053 Evaluation of the effects of melatonin to induce ROS production by reverse electron transport in HNSCC cells presented by Escames Germaine, University of Granada, Spain | CIBERFES, Ibs.Granada, Spain
054 Metabolic vulnerabilities: targeting oxidative phosphorylation in ovarian cancer
Presented by Carmen Ghilardi, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, ITALY

055 Glycine ameliorates paracetamol-induced liver injury in non-alcoholic fatty liver disease by supporting glutathione biosynthesis
Presented by Alia Ghrayeb, Ruth and Bruce Rappaport Faculty of Medicine, Haifa, ISRAEL

056 Molecular mechanism underlying calcitonin (CT)-calcitonin Receptor (CALCR) signaling
Presented by Jayita Goswami, Indian Institute of Science, Bengaluru, INDIA

057 Branched-chain amino acids as oxidative substrate and lipid droplets biogenesis in pancreatic cancer
Presented by Klára Gotvaldová, IPHYS, Prague, CZECH REPUBLIC

058 Comprehensive characterization of human lung squamous cell carcinoma leads to identify high expression of Transferrin Receptor (TFRC) as a mark of poorly immunogenic tumors
Presented by Maria Gutiérrez-Pérez, imas12 | CNIO | CIBERONC, Madrid, SPAIN

059 The multifaceted role of cyclooxygenase-2 (COX-2) and immunomodulatory effects during progression of U87 glioblastoma
Presented by Cathleen Haase-Kohn, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, GERMANY

060 Exploiting extracellular arginine addiction to treat the aggressive childhood cancer neuroblastoma
Presented by Kimberley Hanssen, Children’s Cancer Institute, Sydney, AUSTRALIA | University of New South Wales, Sydney, AUSTRALIA

061 NUDT22 promotes cancer growth through pyrimidine salvage and the TCA cycle
Presented by Patrick Herr, The University of Sheffield, UK

062 Transport of aspartate and glutamate into leukemic cells impedes the effect of chemotherapy treatment
Presented by Katerina Hlozkova, Charles University, Prague, CZECH REPUBLIC

063 Effect of zinc ions, cisplatin and docetaxel on HNSCC cell lines metabolism
Presented by Hana Holcova Polanka, Masaryk University, Brno, CZECH REPUBLIC

064 A 29-gene signature associated with NOX2 discriminates acute myeloid leukemia prognosis and survival
Presented by Carla Ijurko, University of Salamanca, SPAIN

065 Gender impact on the metabolic-related immune surveillance in melanoma
Presented by Marta Iozzo, University of Florence, ITALY

066 Glucose deprivation enhances metformin-mediated inhibition of proliferation by affecting amino acid uptake and polyamine metabolism through down-regulating c-Myc in HepG2 cells
Presented by Sk Ramiz Islam, Saha Institute of Nuclear Physics, Kolkata, West Bengal, INDIA | Homi Bhabha National Institute, Mumbai, Maharashtra, INDIA
067 Glioblastoma cell motility depends on enhanced oxidative stress coupled with mobilization of a sulfurtransferase Presented by Marie-Pierre Junier, CNRS UMR8246, Inserm U1130, Sorbonne Université, Paris, FRANCE

068 Inhibition of hypusination reprograms Prostate Cancer cell metabolism and decreases aggressiveness Presented by Michel Kahi, Université Côte d’Azur, C3M, INSERM U1065 Equipe Cancer, Nice, FRANCE

069 Metabolic rewiring in metastatic lung adenocarcinoma Presented by Vitaliy Kaminskyy, Karolinska institutet, Stockholm, SWEDEN

070 Proline metabolism regulates immunomodulatory functions of cancer associated fibroblasts Presented by Emily Kay, CRUK Beatson Institute, Glasgow, UK

071 IGF2BP2 in colorectal cancer chemoresistance: An integrated approach employing clinical data, patient-derived organoids and xenografts, 2D and 3D cell culture models, and bioinformatics Presented by Sandra Kendzia, Martin Luther University Halle-Wittenberg, Halle, GERMANY

072 Differential regulation of genes by the glucogenic hormone asprosin in ovarian cancer Presented by Rachel Kerslake, Brunel University London, UK

073 A multi-omics approach to investigate the metabolic landscape in non-small cell lung cancer patients with wild-type and mutant KRas Presented by Elena Kochetkova, Karolinska Institute, Stockholm, SWEDEN

074 The essential role of lysosomal complex Ragulator in the control of AMPK activity in melanoma cells Presented by Kateřina Koždoňová, Masaryk University | St. Anne’s University Hospital, Brno, CZECH REPUBLIC

075 Metabolic addiction to oxidative phosphorylation in tumorogenic PD-1high Follicular Helper T cells reveals a new therapeutic target for Angioimmunoblastic T Cell Lymphoma Presented by Adrien Krug, Université Côte d’Azur, C3M, INSERM U1065, Nice, FRANCE

076 Tracing c-Myc Endogenous Expression for Small Molecules Discovery Presented by Agata Kubickova, Palacky University Olomouc, CZECH REPUBLIC

077 Rewiring of amino acid metabolism in Neurofibromatosis type 1-related tumors Presented by Martina La Spina, University of Padua, ITALY

078 Effect of in vitro starvation on the response of breast cancer cells to chemotherapy Presented by Victorine Lacroix, Université de lorraine, Vandoeuvre-lès-Nancy, Lorraine, FRANCE

079 [POSTER SPOTLIGHT] A functional analysis of 180 cancer cell lines reveals conserved intrinsic metabolic programs Presented by Sarah Cherkaou, University Children's Hospital Zurich | ETH Zurich, SWITZERLAND

080 [POSTER SPOTLIGHT] Nutrient priming of the pre-metastatic niche drives metastasis formation Presented by Ginevra Doglioni, VIB Center for Cancer Biology | KU Leuven and Leuven Cancer Institute (LKI), BELGIUM
081 [POSTER SPOTLIGHT] HIRA loss transforms FH-deficient cells
Presented by Lorea Valcarcel-Jimenez, MRC Cancer Unit-University of Cambridge, UK | CECAD, University of Cologne, GERMANY

082 Integrative omics analysis to elucidate potential antitumor mechanisms of ketogenic diets in melanoma
Presented by Roland Lang, University Hospital of the Paracelsus Medical University, Salzburg, AUSTRIA

083 Chronic cycling hypoxia-induced metabolic reprogramming associates with radioresistance in Ewing Sarcoma in vitro
Presented by Safa Larafa, University of Duisburg-Essen, GERMANY | German Cancer Consortium

084 Transaminase-dependent redox and metabolic role into the mitochondrial adaptation of therapy-resistant AML cancer cells
Presented by Laura Lauture, Centre de Recherches en Cancérologie de Toulouse, FRANCE | Université Paul Sabatier, Toulouse, FRANCE

085 The mTOR substrates 4EBP1/2 reprogram cancer metabolism under energetic stress
Presented by Gabriel Leprivier, Universitätsklinikum Düsseldorf, GERMANY

086 DDR2 confers ferroptosis resistance to mammary cancer-associated fibroblast by regulating iron metabolism
Presented by Julien Lesage, Washington University in St. Louis, Missouri, USA

087 Fibroblast-derived lysyl oxidase increases oxidative phosphorylation and stemness in cholangiocarcinoma
Presented by Monika Lewinska, University of Copenhagen, DENMARK

088 Effect of Melatonin in ABC Transporter-Mediated Multidrug Resistance Associated with Mitochondrial Function
Presented by Alba López-Rodriguez, University of Granada, SPAIN | CIBM, Granada, SPAIN

089 Targeting the mitochondrial carrier UCP2: a strategy to improve the immune response against colorectal cancer
Presented by Angèle Luby, Université Paris Cité, CNRS, INSERM, Institut Cochin, F-75014 Paris, FRANCE

090 The metabolic rewiring induced by S-nitrosothiol reductase deficiency promotes immune evasion in colorectal cancer
Presented by Ana Mantrana, IMIBIC, Córdoba, SPAIN

091 Targeting metabolism as a novel therapeutic strategy to suppress oncogenic c-MYC in group 3 medulloblastoma brain tumors
Presented by Emma Martell, University of Manitoba, Winnipeg, MB, CANADA

092 Lipid Metabolism supports the tumorigenic potential of pancreatic cancer stem cells
Presented by Marta Mascaraque, Instituto de Investigación Sanitaria de Aragón, Zaragoza, SPAIN

093 The activation of Toll-like receptor 3 by endogenous ligands released from necrotic cancer cells
Presented by Tanja Matijevic Glavan, Rudjer Boskovic Institute, Zagreb, CROATIA
094 Nutrient availability and metabolic alterations reshaping the tumor-draining lymph node niche Presented by Greta Mattavelli, University Hospital Würzburg, GERMANY

095 A systematic screen for interstitial fluid metabolites that support metastatic seeding in breast cancer Presented by Greta Mattavelli, University Hospital Würzburg, GERMANY

096 Does Na+/K+-ATPase flux drive the Warburg effect in cancer? Presented by Aidan Michaels, King’s College London, UK

097 ELOVL5 lipid elongation in prostate cancer promotes survival through the unfolded protein response Presented by Deanna Miller, University of Adelaide, AUSTRALIA | South Australian Health and Medical Research Institute, Adelaide, AUSTRALIA

098 Role of Aspartate synthesis in tumor development Presented by Mirko Milosevic, Czech Academy of Science, Vestec, CZECH REPUBLIC | Charles University, Prague, CZECH REPUBLIC

099 Metabolomic study in chemotherapy resistance of prostate cancer. Presented by José M. Mora-Rodríguez, University of Alcalá, Madrid, SPAIN

100 The extracellular matrix promotes breast cancer cell growth under amino acid starvation by promoting tyrosine catabolism Presented by Mona Nazemi, The University of Sheffield, UK

101 Implication of cholesterol metabolism in the development of Colorectal Liver Metastasis Presented by Ane Nieva-Zuluaga, University of the Basque Country UPV/EHU, Leioa, SPAIN

102 Chaperone-mediated Autophagy Deficiency Reprograms Cancer Metabolism Via TGF-β Signaling to Drive Mesenchymal Tumor Growth Presented by Erik Norberg, Karolinska Institute, Stockholm, SWEDEN

103 The expression pattern of pyruvate dehydrogenase kinases predicts prognosis in clear cell renal cell carcinoma Presented by Caroline Nunes-Xavier, Biocruces Bizkaia Health Research Institute, Barakaldo, SPAIN | Oslo University Hospital Radiumhospitalet, NORWAY

104 The splicing factor PTBP1 is a key regulator of acute myeloid leukemia metabolism and survival Presented by Margaux Oberling, Centre de Recherches en Cancérologie de Toulouse, FRANCE | Université Toulouse III-Paul Sabatier, Toulouse, FRANCE

105 SOS-RAS GEFs as potential therapeutic targets in cancer and metabolism Presented by Andrea Olarte, Centro de investigación del cáncer, Salamanca, SPAIN

106 Decoupling of the Warburg effect from glycolytic activity Presented by Angela M. Otto, Technical University of Munich, GERMANY
107 Mitochondrial trafficking in the tumor microenvironment (TME): Role beyond energy modulation in breast cancer Presented by Sameer Kumar Panda, University of Campania “Luigi Vanvitelli”, Naples, ITALY

108 Mitochondrial alterations induce metabolic and epigenetic rewiring in Pancreatic Ductal Adenocarcinoma Presented by Carlotta Paoli, Veneto Institute of Molecular Medicine, VIMM, Padova, ITALY | UNIPD, Padova, ITALY

109 Virtual microdissection of non-small cell lung cancer identifies transcriptome-based tumor-specific and immune-specific molecular subtypes Presented by Sushant Parab, University of Torino, ITALY | Candido Cancer Institute – IRCCS, Candiolo, ITALY

110 Stromal lactid acid protects prostate cancer cells from ferroptosis Presented by Elisa Pardella, University of Florence, ITALY

111 Nuclear MTHFD2 regulates centromere stability during mitosis Presented by Natalia Pardo-Lorente, Centre for Genomic Regulation, Barcelona, SPAIN

112 Exercise Forms a Metabolic Shield in Distant Organs Blocking Cancer Progression and Metastatoc Dissemination Presented by Shivang Parikh, Tel Aviv University, ISRAEL

113 Characterization of metabolic profile of acute myeloid leukaemia cells resistant to chemotherapy Presented by Joana Pereira-Vieira, University of Minho, Braga, PORTUGAL | ICVS/3B’s - PT Government Associate Laboratory, Braga/Guimarães, PORTUGAL

114 Pancreatic progenitors expressing the metabolic regulator Aldh1b1 potentially initiate pancreatic ductal adenocarcinoma Presented by Ivan Perez-Rodriguez, TU Dresden, Helmholtz Zentrum München, GERMANY | German Centre for Diabetes Research (DZD), Munich, GERMANY

115 Inhibition of BET proteins unveils a novel mechanism of lipid homeostasis mediated by ATGL in triple-negative breast cancer (TNBC) Presented by Mariaelena Pistoni, Azienda USL-IRCCS di Reggio Emilia, ITALY

116 Gmcstool: Automated Network-Based Tool to Search for Metabolic Vulnerabilities in Cancer Presented by Francisco Planes, TECNUN, University of Navarra, San Sebastian, SPAIN

117 Mimicking ketosis reverses key hallmarks of tumorigenesis in glioma cells Presented by Phillip Pöller, DKFZ, Heidelberg, GERMANY

118 Identification of metabolic targets in melanoma using physiologically relevant in vitro models Presented by Jasmin Preis, University of Luxembourg, Belvaux, LUXEMBOURG

119 Ablation of MNK1 kinase reshapes the metabolic profile and secretome of 4T1 cells to diminish liver metastasis Presented by Samuel Preston, McGill University | Segal Cancer Centre, Montréal, Québec, CANADA
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Presenter and Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>120</td>
<td>Metabolic vulnerabilities associated to BRCA1 induced metabolic rewiring</td>
<td>Presented by Leonor Puchades-Carrasco, Institute of Cancer Research, London, UK</td>
</tr>
<tr>
<td>121</td>
<td>Polyamine deprivation therapy confers a survival advantage to prostate cancer cells through the activation of ATF4 signaling</td>
<td>Presented by Mikel Pujana-Vaquerizo, CIC bioGUNE, Derio, SPAIN</td>
</tr>
<tr>
<td>122</td>
<td>Differential acquisition of extracellular lipid correlates with pancreatic cancer subtype and metastasis to the liver</td>
<td>Presented by Gilles Rademaker, University of California, San Francisco, USA</td>
</tr>
<tr>
<td>123</td>
<td>Targeting loss of heterozygosity in colorectal cancer</td>
<td>Presented by Natallia Rameika, Uppsala University, SWEDEN</td>
</tr>
<tr>
<td>124</td>
<td>Effect of melatonin on Bmal1 and the relationship in tumor proliferation</td>
<td>Presented by César Rodríguez-Santana, University of Granada</td>
</tr>
<tr>
<td>125</td>
<td>Fumarate hydratase (FH) activity is altered by histone deacetylase 6 (HDAC6) in triple negative breast cancer cells</td>
<td>Presented by Andrew Roe, Royal College of Surgeons in Ireland, Dublin, IRELAND</td>
</tr>
<tr>
<td>126</td>
<td>Mitochondrial Her2 promotes tumorigenicity by stimulating respiration</td>
<td>Presented by Jakub Rohlena, Institute of Biotechnology of the Czech Academy of Sciences, Prague, CZECH REPUBLIC</td>
</tr>
<tr>
<td>127</td>
<td>Revealing the role of NOX2-NOX4 axis on mitochondrial metabolism: implications for Chronic Myeloid Leukemia</td>
<td>Presented by Marta Romo-González, University of Salamanca, SPAIN</td>
</tr>
<tr>
<td>128</td>
<td>In vitro models to study the adipocyte-tumor microenvironment and its impact on the metabolism of colon cancer cells</td>
<td>Presented by Veronica Ruiz-Torres, Universitas Miguel Hernández (UMH), Alicante, SPAIN</td>
</tr>
<tr>
<td>129</td>
<td>Activation of the miR-210-ISCU axis is a common adverse feature of hypoxic cancers</td>
<td>Presented by Jaime San-Juan-Guardado, Institute of Sanitary Research of the Principality of Asturias, Oviedo, SPAIN</td>
</tr>
<tr>
<td>130</td>
<td>Capsaicin induces antitumoral effects in prostate cancer cells through the TRPV1/LKB1/AMPK pathway</td>
<td>Presented by Belén G. Sánchez, University of Alcalá, Madrid, SPAIN</td>
</tr>
<tr>
<td>131</td>
<td>The fa(s)t conquest of prostate cancer cells in the bone niche</td>
<td>Presented by Pablo Sanchis, Universidad de Buenos Aires</td>
</tr>
<tr>
<td>132</td>
<td>PPAR-delta acts as a metabolic master checkpoint for metastasis in pancreatic cancer cells</td>
<td>Presented by Patricia Sancho, IIS Aragon, Zaragoza, SPAIN</td>
</tr>
</tbody>
</table>
133 The role of Notch3 in the resistance to taxanes
Presented by Cristian Sandoval-Acuña, Institute of Biotechnology of the Czech Academy of Sciences, Vestec, CZECH REPUBLIC

134 MitoTracker Deep Red (MTDR) Is a Metabolic Inhibitor for Targeting Mitochondria and Eradicating Cancer Stem Cells (CSCs), With Anti-Tumor and Anti-Metastatic Activity In Vivo
Presented by Camillo Sargiacomo, Salford University, Salford, UK | Lunella Biotech, Inc., Ottawa, CANADA

135 Metformin Modifies Mitochondrial Functionality in an Obesity-Associated Inflammation in Breast Cancer Cell Lines According to the Eralpha/Erbbeta Ratio
Presented by Jorge Sastre-Serra, Universitat de les Illes Balears, Palma, SPAIN | CIBER Fisiopatología Obesidad y Nutrición (CB06/03), Madrid, SPAIN

136 Targeting the translational machinery to overcome kinase inhibitor resistance of melanoma cells
Presented by Alejandro Schoclnik-Cabrera, Université de Montréal, CANADA | Centre de recherche de l'Hôpital Maisonneuve-Rosemont, Montréal, CANADA

137 Signature Regulatory Clustering (SiRCle) model integration reveals mechanisms of phenotype regulation in renal cancer
Presented by Christina Schmidt, CECAD Research Center, University Hospital Cologne, GERMANY

138 Predicting anticancer drug Mode of Action using high-throughput metabolomics
Presented by Laurentz Schuhknecht, ETH Zürich, SWITZERLAND

139 A fat lot of good; the role of a monounsaturated fatty acid in regulating prostate cancer cell growth and survival
Presented by Julia Scott, The University of Adelaide Medical School, AUSTRALIA | Freemasons Centre for Male Health and Wellbeing, Adelaide, AUSTRALIA

140 Advantages of in vitro 3D bioprinted cancer models in metabolic characterisation and anti-metabolic drug combination tests
Presented by Anna Sebestyén, Semmelweis University, Budapest, HUNGARY

141 Contrasting effects of lactate transporter inhibition in combination with metformin in T-cell acute lymphoblastic leukaemia
Presented by Emma Stanton, Swansea University Medical School, Swansea, UK

142 Chimeric JAK2 kinases trigger non-uniform changes of cellular metabolism in BCR-ABL1-like childhood ALL
Presented by Julia Starkova, CLIP - Childhood Leukaemia Investigation Prague | Charles University and University Hospital Motol, Prague, CZECH REPUBLIC

143 Primary cilia sense nutrients availability and respond to glutamine via asparagine synthetase
Presented by Maria Elena Steidl, IRCCS San Raffaele Scientific Institute | Vita-Salute San Raffaele University, Milan, ITALY

144 The role of Pdh1α as an epigenetic regulator in triple-negative breast cancer fibroblasts
Presented by Britt Amber Sterken, CRUK Beatson Institute, Glasgow, UK
145 Identification of the Warburg effect in pediatric hematological malignancies and its response under nutrient restriction Presented by Ziqin Tang, Princess Máxima Center for Pediatric Oncology | Oncode Institute, Utrecht, NETHERLANDS

146 Gastric Cancer Spheroids Exhibit Drug Resistance and Metabolic Alterations Compared to their 2D Culture Counterparts Presented by Hilal Taşkıran, Koç University, Istanbul, TURKEY

147 Epigenetic moldulation of cancer stem cell metabolism as therapy for PDAC Presented by Kanishka Tiwary, Ulm University, GERMANY

148 MYC inhibition has therapeutic potential in PGC1-low aggressive prostate cancer Presented by Verónica Torrán, University of the Basque Country, Leioa, SPAIN | CIBERONC, Madrid, SPAIN

149 Heterogeneity in lipid handling in pancreatic ductal adenocarcinoma subtypes Presented by Marija Trajkovic-Arsic, University Hospital Essen | DKFZ, Heidelberg, Essen, GERMANY

150 Depot-specific and stem cell-specific metabolic alterations in adipose tissue may contribute to a cancer-permissive microenvironment Presented by Elisabetta Trevislin, University Hospital of Padua, ITALY

151 BACE2 regulates lipid homeostasis and energetic metabolism in melanoma cells Presented by Laura Tronci, Cogentech SRL Benefit Corporation, Milan, ITALY

152 Identifying targetable metabolic dependencies across colorectal cancer progression Presented by Emma Vincent, University of Bristol, UK

153 Induction of metabolic switch from glucose to alternate metabolism sustains lung tumor-initiating cell function Presented by Zhengwei Wu, Genome Institute of Singapore | Cancer Science Institute of Singapore

154 Investigating synthetic lethality associated with NF1 loss Presented by Manuela Ye, Université de Paris, FRANCE

155 Metabolic syndrome increases castration resistance in prostate cancer Presented by Amaia Zabala-Letona, cicBIOGUNE, DERIO, SPAIN | CIBERONC, Madrid, SPAIN

156 White adipocytes cause changes in lipidomic profile of cancer cells in cancer cachexia model Presented by Jelena Zurkovic, University of Bonn, LIMES Institute, GERMANY

157 Myeloid MCT1 deficiency promotes tumor vessel normalization Presented by Katrien De Bock, DHEST, Zurich, SWITZERLAND

158 Protein folding in metabolic reprogramming Presented by Barak Rotblat, Ben Gurion University of the Negev | NIBN, Beer Sheva, ISRAEL
Save the date

eacr.org/conference

EACR Conference
THE INVISIBLE PHASE OF METASTASIS
Impact of dormancy, cancer cell plasticity and evolution of the niche during metastatic progression

VIRTUAL EVENT
06-07 December 2022

MIND THE GAP:
EACR Conference
TRAILBLAZING CANCER PREVENTION

Virtual event
31 January 2023

EACR-AACR Basic & Translational Research Conference
Florence, Italy | 15 - 17 March 2023
IMMUNE RESPONSES & DNA REPAIR
CANCER FIELDS CONVERGING

EACR Conference
DEFENCE IS THE BEST ATTACK
Immuno-Oncology Breakthroughs

Barcelona, Spain
09 - 11 May 2023

Plus more 2023 conferences:
• Drugging and Regulating the MAP Kinase Pathway
• Molecular Pathology Approach to Cancer
• Early Career Researchers' Conference
• Goodbye Flat Biology: Next Generation Cancer Models
• Epigenetics

Don’t forget the next EACR Congress... eacr2023.org

EACR 2023
Innovative Cancer Science
12-15 June 2023
Torino, Italy
ANNUAL CONGRESS OF THE EUROPEAN ASSOCIATION FOR CANCER RESEARCH
The European Association for Cancer Research gratefully acknowledges our Industry Partners, who offer ongoing support to the EACR and provide the means for the Association to develop important initiatives.

eacr.org/conference/cancermetabolism2022